Daniel Lu is Chairman of the Board of the Company and AHS.

Mr. Lu is a seasoned healthcare entrepreneur with extensive operation in China. He has been serving as Chairman of the Board for the DaoPei Medical Group (“DPMG”) since 2010. Under his leadership, DPMG has recently expanded its clinical network involving a state-of-the-art stem cell bank at Wuhan Biolake, three top-ranked private hospitals (located in Beijing, Shanghai, and Hebei), specialty hematology laboratories, as well as a hematology research institute, with more than 100 partnering and collaborating hospitals in China. DPMG was founded by Professor Daopei Lu, a renowned hematologist pioneering in hematopoietic stem cell transplant and member of the Academy of Engineering in China.

Mr. Lu received a Bachelor of Arts from Temple University Tyler School of Arts in 1988 and subsequently worked as senior Art Director at Ogilvy & Mather Advertising Company. Prior to joining DPMG, Mr. Lu served as Chief Operating Officer for BioTime Asia Limited which is a subsidiary of BioTime, Inc. (NYSE/AMEX:BTX) in 2009.

David Jin, MD, Ph.D., a director and Chief Executive Officer of the Company and AHS.

From 2009 to 2016, Dr. Jin has served as the Chief Medical Officer of BioTime, Inc. (NYSE MKT: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology.

Dr. Jin also acts as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University.

Prior to his current endeavors, Dr. Jin was Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based technology development. Dr. Jin has been Principle Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters.

Dr. Jin studied medicine at SUNY Downstate College of Medicine in Brooklyn, NY. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology.

Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015.

Congressman Tauzin has a long and distinguished 36-year elective career culminating in chairing the Energy and Commerce Committee (ECC) in the U.S. House of Representatives, which oversees food and drug safety, public health and research, telecommunications, consumer protection, environmental quality, energy policy, and interstate and foreign commerce among others.

After leaving Congress in 2005, Congressman Tauzin was invited to become the President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he oversaw their participation in putting together the Partnership for Prescription Assistance, which has provided free and nearly free medication for over 10 million patients.

Congressman Tauzin now serves on the Boards of Directors of Entergy Corporation, LHC Group, the Alliance for Aging Research, Lenitiv Scientific, CaptureRx, and Resilient Network Systems, Inc. In 2010, he founded Tauzin Strategic Networks and co-founded Tauzin Consultants, LLC, a DC-based government relations, advocacy and strategic counsel organizations, fostering innovative solutions to some of the world's biggest challenges.

Dr. Troy currently serves as Vice President of Public Policy for Juul Labs. He brings extensive senior level government and industry experience having served the White House in several high-level positions, including Deputy Secretary of the U.S. Department of Health and Human Services (HHS), as well as Deputy Assistant and then Acting Assistant to the President for Domestic Policy. As Deputy Secretary of HHS, Dr. Troy oversaw the largest civilian department in the federal government, with a budget of $716 billion and over 67,000 employees. From 2014 to 2018, Dr. Troy was the founder and CEO of the American Health Policy Institute. He also served as a Senior Fellow at Hudson Institute, where he remains an Adjunct Fellow, and was a researcher at the American Enterprise Institute. From 1998 to 2000, Dr. Troy served as the Policy Director for Senator John Ashcroft. From 1996 to 1998, Troy was Senior Domestic Policy Adviser and later Domestic Policy Director for the House Policy Committee, chaired by Congressman Christopher Cox.

Dr. Troy's other affiliations include: contributing editor for Washingtonian magazine; member of the publication committee of National Affairs; member of the Board of Fellows of the Jewish Policy Center; member of the Board of Directors of R Street; a Senior Fellow at the Potomac Institute; and a member of the Blue Ribbon Study Panel examining the United States’ readiness to address bioterrorism and naturally occurring outbreaks. In 2012, he was a Special Policy Adviser to the Mitt Romney presidential campaign and served as Director of Domestic Policy for the nascent Romney transition. Dr. Troy has a B.S. in Industrial and Labor Relations from Cornell University and an M.A and Ph.D. in American Civilization from the University of Texas at Austin.

Mr. Stilley currently serves as Chief Executive Officer of Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder. Prior to joining Adial, he was the Vice President, Business Development & Strategic Projects at Clinical Data, Inc. At Clinical Data, Inc.

Mr. Stilley worked on licensing and M&A transactions and was involved in management of Phase 3 clinical trials, production of Viibryd® for initial commercial launch of the product, and sourcing drug product and drug substance for the Phase 3 clinical trials of the company’s vasodilator drug for myocardial stress imaging. Mr. Stilley also served as the COO and CFO of Adenosine Therapeutics, LLC where he ran the internal operations of the company, including research and development, and all financing activity, until the sale of its principal assets to Clinical Data, Inc.

Mr. Stilley has advised both public and private companies on financing and M&A transactions, has been the interim CFO of a public company, the interim Chief Business Officer of Diffusion Pharmaceuticals, and the COO and CFO of a number of private companies.

Before entering the business community, Mr. Stilley served as Captain in the U.S. Marine Corps. Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. He has guest lectured at the Darden School of Business on the management of life science companies and serves on the Board of Virginia BIO, the statewide biotechnology organization. He also holds patents for Stedivaze®, which is currently in Phase 3 clinical development.

Mr. Sanders brings over four decades of experience within the specialized areas of corporate, securities and international law. He has experience representing life science companies including both public and private companies. He has also represented both underwriters and issuers on a variety of public and private financings.

Mr. Sanders has held senior positions at leading U.S. and international law firms, and founded the Ortoli Rosenstadt LLP law firm, headquartered in New York City, which has represented both domestic and international clients across many industries including life sciences, in areas such as mergers, acquisitions and a variety of other transactions. Steven is a member of the American Bar Association and the New York State Bar Association and the Bar of the City of New York, where he previously served on the European Affairs Committee.

In addition, Mr. Sanders sits on the boards of other companies including Helijet International, Inc. and Electrameccanica Vehicles, as well as non-profits such as the American Academy of Dramatic Arts, and the Bay Street Theater. He previously served on the board of the Roundabout Theatre Company, the largest non-profit theater in America and Town Hall. He also was the former Honorary Consul from the Republic of Moldova.

Yancen Lu has more than 19 years’ experience in investment banking and equity investment management.

Mr. Lu is Managing Director of FountainVest Partners. Besides his professionalism in securities, investment and capital management, Mr Lu has special focus and comprehensive understanding of the global medical and healthcare industry, he is Director of leading healthcare corporations including Sino Hospital Investment Corporation (Hong Kong), Chang’an Hospital (the largest private hospital in Northwest China), and DIH Medical Technologies.

Mr. Lu received Bachelor and Master degrees of Engineering Economics from Tianjin University.